{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:00:52Z","timestamp":1791820852878,"version":"4.3.4"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ejim.2024.10.015","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T22:13:26Z","timestamp":1729635206000},"page":"27-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Chronic obstructive pulmonary disease's eosinophilic phenotype: Clinical characteristics, biomarkers and biotherapy"],"prefix":"10.1016","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6751-9921","authenticated-orcid":false,"given":"Mauro","family":"Maniscalco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Candia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Ambrosino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Iovine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Fuschillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejim.2024.10.015_bib0001","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00164-2019","article-title":"Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019","volume":"53","author":"Singh","year":"2019","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ejim.2024.10.015_bib0002","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2500\/aap.2015.36.3812","article-title":"Burden of chronic obstructive pulmonary disease: healthcare costs and beyond","volume":"36","author":"May","year":"2015","journal-title":"Allergy Asthma Proc"},{"issue":"9","key":"10.1016\/j.ejim.2024.10.015_bib0003","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1164\/rccm.202003-0625ST","article-title":"Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline","volume":"201","author":"Nici","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.ejim.2024.10.015_bib0004","article-title":"Anti-IL-5 therapies for chronic obstructive pulmonary disease","volume":"12","author":"Donovan","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.ejim.2024.10.015_bib0005","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00651-2019","article-title":"Airway inflammation in COPD: progress to precision medicine","volume":"54","author":"Brightling","year":"2019","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.ejim.2024.10.015_bib0006","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1164\/rccm.201502-0235LE","article-title":"Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone\/Formoterol in Chronic Obstructive Pulmonary Disease","volume":"192","author":"Siddiqui","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.ejim.2024.10.015_bib0007","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/thoraxjnl-2020-215167","article-title":"Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait","volume":"76","author":"David","year":"2021","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.ejim.2024.10.015_bib0008","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12931-017-0559-0","article-title":"Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma","volume":"18","author":"Kolsum","year":"2017","journal-title":"Respir Res"},{"issue":"5","key":"10.1016\/j.ejim.2024.10.015_bib0009","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(16)00100-4","article-title":"Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial","volume":"4","author":"Watz","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.ejim.2024.10.015_bib0010","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1164\/rccm.201701-0009LE","article-title":"Stability of Blood Eosinophils in Patients with Chronic Obstructive Pulmonary Disease and in Control Subjects, and the Impact of Sex, Age, Smoking, and Baseline Counts","volume":"195","author":"Oshagbemi","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.ejim.2024.10.015_bib0011","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1183\/13993003.01659-2015","article-title":"Blood eosinophil count to predict bronchial eosinophilic inflammation in COPD","volume":"47","author":"Schleich","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejim.2024.10.015_bib0012","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.2147\/COPD.S179734","article-title":"Blood eosinophil count as a prognostic biomarker in COPD","volume":"13","author":"Oh","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"6","key":"10.1016\/j.ejim.2024.10.015_bib0013","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1164\/rccm.201104-0597OC","article-title":"Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers","volume":"184","author":"Bafadhel","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.ejim.2024.10.015_bib0014","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1164\/rccm.201509-1869OC","article-title":"Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study","volume":"193","author":"Vedel-Krogh","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ejim.2024.10.015_bib0015","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.2147\/COPD.S330817","article-title":"Treatable Traits in COPD - A Proposed Approach","volume":"16","author":"Cardoso","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"6","key":"10.1016\/j.ejim.2024.10.015_bib0016","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1183\/09031936.00162414","article-title":"Eosinophilic inflammation in COPD: prevalence and clinical characteristics","volume":"44","author":"Singh","year":"2014","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.ejim.2024.10.015_bib0017","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00184-2021","article-title":"Upper airway symptoms associate with the eosinophilic phenotype of COPD","volume":"7","author":"Obling","year":"2021","journal-title":"ERJ Open Res"},{"issue":"1","key":"10.1016\/j.ejim.2024.10.015_bib0018","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00772-2020","article-title":"Pulmonary hypertension in eosinophilic versus noneosinophilic COPD","volume":"7","author":"Alzghoul","year":"2021","journal-title":"ERJ Open Res"},{"issue":"10","key":"10.1016\/j.ejim.2024.10.015_bib0019","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.arbres.2017.01.014","article-title":"Post-bronchodilator Reversibility of FEV(1) and Eosinophilic Airway Inflammation in COPD","volume":"53","author":"Chou","year":"2017","journal-title":"Arch Bronconeumol"},{"issue":"1","key":"10.1016\/j.ejim.2024.10.015_bib0020","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12931-018-0840-x","article-title":"Serial blood eosinophils and clinical outcome in patients with chronic obstructive pulmonary disease","volume":"19","author":"Shin","year":"2018","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.ejim.2024.10.015_bib0021","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12931-019-1130-y","article-title":"Evaluation of exacerbations and blood eosinophils in UK and US COPD populations","volume":"20","author":"Vogelmeier","year":"2019","journal-title":"Respir Res"},{"key":"10.1016\/j.ejim.2024.10.015_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106092","article-title":"Chronic rhinosinusitis in COPD: A prevalent but unrecognized comorbidity impacting health related quality of life","volume":"171","author":"Arndal","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.ejim.2024.10.015_bib0023","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.2147\/COPD.S165857","article-title":"Clinical impact of nasal budesonide treatment on COPD patients with coexistent rhinitis","volume":"13","author":"Calabrese","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"8","key":"10.1016\/j.ejim.2024.10.015_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24087254","article-title":"Eosinophilic Airway Diseases: From Pathophysiological Mechanisms to Clinical Practice","volume":"24","author":"Mormile","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.ejim.2024.10.015_bib0025","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00838-2020","article-title":"Can CCRG, authors would also like to thank the m, women who participated in the s, individuals in the Can CCRGnlaa. High eosinophil counts predict decline in FEV(1): results from the CanCOLD study","volume":"57","author":"Tan","year":"2021","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.ejim.2024.10.015_bib0026","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01037-2023","article-title":"The association of blood eosinophil counts and FEV(1) decline: a cohort study","volume":"63","author":"Hong","year":"2024","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ejim.2024.10.015_bib0027","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/s12890-024-03062-1","article-title":"Monitoring COPD patients: systemic and bronchial eosinophilic inflammation in a 2-year follow-up","volume":"24","author":"Pignatti","year":"2024","journal-title":"BMC Pulm Med"},{"issue":"2","key":"10.1016\/j.ejim.2024.10.015_bib0028","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00437-2020","article-title":"Targeted therapy in eosinophilic chronic obstructive pulmonary disease","volume":"7","author":"Fieldes","year":"2021","journal-title":"ERJ Open Res"},{"issue":"4","key":"10.1016\/j.ejim.2024.10.015_bib0029","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1164\/rccm.202303-0455CI","article-title":"Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic Obstructive Pulmonary Disease: A Biologics Outlook","volume":"208","author":"Rabe","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.ejim.2024.10.015_bib0030","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/all.14661","article-title":"Type 2 inflammation in eosinophilic chronic obstructive pulmonary disease","volume":"76","author":"Higham","year":"2021","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.ejim.2024.10.015_bib0031","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/all.14016","article-title":"Blood eosinophil count and airway epithelial transcriptome relationships in COPD versus asthma","volume":"75","author":"George","year":"2020","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.ejim.2024.10.015_bib0032","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12931-018-0807-y","article-title":"The association between airway eosinophilic inflammation and IL-33 in stable non-atopic COPD","volume":"19","author":"Tworek","year":"2018","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.ejim.2024.10.015_bib0033","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1021\/acsptsci.9b00099","article-title":"IL-33 in Chronic Respiratory Disease: From Preclinical to Clinical Studies","volume":"3","author":"Donovan","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"6","key":"10.1016\/j.ejim.2024.10.015_bib0034","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00408-021-00492-0","article-title":"Eosinophilic Chronic Obstructive Pulmonary Disease","volume":"199","author":"Weissler","year":"2021","journal-title":"Lung"},{"issue":"43","key":"10.1016\/j.ejim.2024.10.015_bib0035","doi-asserted-by":"crossref","first-page":"15502","DOI":"10.1073\/pnas.1410700111","article-title":"Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells","volume":"111","author":"Lefrancais","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejim.2024.10.015_bib0036","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-024-01048-y","article-title":"Spatial adaptation of eosinophils and their emerging roles in homeostasis, infection and disease","author":"Arnold","year":"2024","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1016\/j.ejim.2024.10.015_bib0037","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41577-018-0006-6","article-title":"Targeting cytokines to treat asthma and chronic obstructive pulmonary disease","volume":"18","author":"Barnes","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.ejim.2024.10.015_bib0038","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000455395","article-title":"Personalised Medicine for Asthma and Chronic Obstructive Pulmonary Disease","volume":"93","author":"Heaney","year":"2017","journal-title":"Respiration"},{"key":"10.1016\/j.ejim.2024.10.015_bib0039","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.2147\/COPD.S100338","article-title":"Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD","volume":"11","author":"Negewo","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.ejim.2024.10.015_bib0040","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.rmed.2018.03.016","article-title":"Blood eosinophil levels as a biomarker in COPD","volume":"138","author":"Brusselle","year":"2018","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.ejim.2024.10.015_bib0041","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00633-2019","article-title":"Blood eosinophil counts in COPD patients compared to controls","volume":"54","author":"Kolsum","year":"2019","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.ejim.2024.10.015_bib0042","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.alit.2022.11.012","article-title":"Blood eosinophil count variability in chronic obstructive pulmonary disease and severe asthma","volume":"72","author":"Abe","year":"2023","journal-title":"Allergol Int"},{"issue":"1","key":"10.1016\/j.ejim.2024.10.015_bib0043","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12931-020-1279-4","article-title":"The stability of blood Eosinophils in chronic obstructive pulmonary disease","volume":"21","author":"Long","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.ejim.2024.10.015_bib0044","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.2147\/COPD.S401357","article-title":"Variability of Blood Eosinophil Count at Stable-State in Predicting Exacerbation Risk of Chronic Obstructive Pulmonary Disease","volume":"18","author":"Kwok","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"10.1016\/j.ejim.2024.10.015_bib0064","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/resp.12687","article-title":"Effect of treatment with inhaled corticosteroid on serum periostin levels in asthma","volume":"21","author":"Hoshino","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.ejim.2024.10.015_bib0065","doi-asserted-by":"crossref","first-page":"137","DOI":"10.18433\/jpps32306","article-title":"Periostin: A Potential Biomarker and Therapeutic Target in Pulmonary Diseases","volume":"25","author":"Alzobaidi","year":"2022","journal-title":"J Pharm Pharm Sci"},{"issue":"1","key":"10.1016\/j.ejim.2024.10.015_bib0066","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12931-018-0818-8","article-title":"Serum periostin does not reflect type 2-driven inflammation in COPD","volume":"19","author":"Carpaij","year":"2018","journal-title":"Respir Res"},{"key":"10.1016\/j.ejim.2024.10.015_bib0067","article-title":"MCP-4 and Eotaxin-3 Are Novel Biomarkers for Chronic Obstructive Pulmonary Disease","volume":"2023","author":"Fang","year":"2023","journal-title":"Can Respir J"},{"issue":"1","key":"10.1016\/j.ejim.2024.10.015_bib0068","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12931-017-0662-2","article-title":"The value of blood cytokines and chemokines in assessing COPD","volume":"18","author":"Bradford","year":"2017","journal-title":"Respir Res"},{"key":"10.1016\/j.ejim.2024.10.015_bib0070","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2147\/COPD.S184097","article-title":"Overexpression of chitotriosidase and YKL-40 in peripheral blood and sputum of healthy smokers and patients with chronic obstructive pulmonary disease","volume":"14","author":"Majewski","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"8","key":"10.1016\/j.ejim.2024.10.015_bib0071","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9082670","article-title":"Role of Type2 Inflammatory Biomarkers in Chronic Obstructive Pulmonary Disease","volume":"9","author":"Oishi","year":"2020","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.ejim.2024.10.015_bib0060","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1183\/09031936.00162912","article-title":"Aspergillus fumigatus during stable state and exacerbations of COPD","volume":"43","author":"Bafadhel","year":"2014","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ejim.2024.10.015_bib0061","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12931-014-0130-1","article-title":"The prevalence of increased serum IgE and Aspergillus sensitization in patients with COPD and their association with symptoms and lung function","volume":"15","author":"Jin","year":"2014","journal-title":"Respir Res"},{"issue":"6","key":"10.1016\/j.ejim.2024.10.015_bib0062","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.chest.2020.04.069","article-title":"Clinical Phenotypes of Atopy and Asthma in COPD: A Meta-analysis of SPIROMICS and COPDGene","volume":"158","author":"Putcha","year":"2020","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.ejim.2024.10.015_bib0063","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1164\/rccm.201211-2103OC","article-title":"Effects of allergic phenotype on respiratory symptoms and exacerbations in patients with chronic obstructive pulmonary disease","volume":"188","author":"Jamieson","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.ejim.2024.10.015_bib0045","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10092128","article-title":"Blood Eosinophils and Exhaled Nitric Oxide: Surrogate Biomarkers of Airway Eosinophilia in Stable COPD and Exacerbation","volume":"10","author":"Antus","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejim.2024.10.015_bib0046","doi-asserted-by":"crossref","DOI":"10.2174\/0109298673289734231228105444","article-title":"Exploring the Role of Nitric Oxide in Lower Airway Diseases: Insights and Real-world Application","author":"Ambrosino","year":"2024","journal-title":"Curr Med Chem"},{"issue":"21","key":"10.1016\/j.ejim.2024.10.015_bib0047","doi-asserted-by":"crossref","DOI":"10.3390\/cells12212518","article-title":"Path-2 Task F. Exhaled Nitric Oxide as Biomarker of Type 2 Diseases","volume":"12","author":"Maniscalco","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ejim.2024.10.015_bib0048","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.2147\/COPD.S165780","article-title":"Exhaled nitric oxide in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"13","author":"Lu","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.ejim.2024.10.015_bib0049","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.2147\/COPD.S257965","article-title":"Predictive Value of Exhaled Nitric Oxide and Blood Eosinophil Count in the Assessment of Airway Eosinophilia in COPD","volume":"15","author":"Antus","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.ejim.2024.10.015_bib0050","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2147\/COPD.S134998","article-title":"Correlation between fractional exhaled nitric oxide and sputum eosinophilia in exacerbations of COPD","volume":"12","author":"Gao","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"10.1016\/j.ejim.2024.10.015_bib0051","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/15412555.2019.1704231","article-title":"Fractional Exhaled Nitric Oxide is Associated with the Severity of Stable COPD","volume":"17","author":"Liu","year":"2020","journal-title":"COPD"},{"key":"10.1016\/j.ejim.2024.10.015_bib0052","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.2147\/COPD.S263673","article-title":"The Value of FENO Measurement for Predicting Treatment Response in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease","volume":"15","author":"Zhou","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"10.1016\/j.ejim.2024.10.015_bib0053","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1080\/07853890.2021.1979242","article-title":"Performance of fractional exhaled nitric oxide in predicting response to inhaled corticosteroids in chronic cough: a meta-analysis","volume":"53","author":"Ambrosino","year":"2021","journal-title":"Ann Med"},{"issue":"11","key":"10.1016\/j.ejim.2024.10.015_bib0054","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12111906","article-title":"Fractional Exhaled Nitric Oxide (FeNO) in Patients with Stable Chronic Obstructive Pulmonary Disease: Short-Term Variability and Potential Clinical Implications","volume":"12","author":"Ambrosino","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.ejim.2024.10.015_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106377","article-title":"The role of FeNO in stable COPD patients with eosinophilic airway inflammation","volume":"181","author":"Vincken","year":"2021","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.ejim.2024.10.015_bib0056","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1007\/s10753-013-9653-8","article-title":"Predicting sputum eosinophilia in exacerbations of COPD using exhaled nitric oxide","volume":"36","author":"Soter","year":"2013","journal-title":"Inflammation"},{"issue":"4","key":"10.1016\/j.ejim.2024.10.015_bib0057","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/15412555.2018.1485637","article-title":"Investigating Fractional Exhaled Nitric Oxide in Chronic Obstructive Pulmonary Disease (COPD) and Asthma-COPD Overlap (ACO): A Scoping Review","volume":"15","author":"Mostafavi-Pour-Manshadi","year":"2018","journal-title":"COPD"},{"key":"10.1016\/j.ejim.2024.10.015_bib0058","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.crimmu.2022.03.002","article-title":"The emerging roles of eosinophils: Implications for the targeted treatment of eosinophilic-associated inflammatory conditions","volume":"3","author":"Lombardi","year":"2022","journal-title":"Curr Res Immunol"},{"issue":"8","key":"10.1016\/j.ejim.2024.10.015_bib0059","article-title":"Update on the Role of FeNO in Asthma Management","volume":"13","author":"Murugesan","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"5","key":"10.1016\/j.ejim.2024.10.015_bib0069","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.jaci.2023.02.005","article-title":"Cystatin SN in type 2 inflammatory airway diseases","volume":"151","author":"Yan","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.ejim.2024.10.015_bib85","doi-asserted-by":"crossref","first-page":"1801941","DOI":"10.1183\/13993003.01941-2018","article-title":"A pilot study to test the feasibility of histological characterisation of asthma-COPD overlap","volume":"53","author":"Papakonstantinou","year":"2019","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ejim.2024.10.015_bib88","doi-asserted-by":"crossref","first-page":"2300218","DOI":"10.1183\/13993003.00218-2023","article-title":"Airway smooth muscle area to predict steroid responsiveness in COPD patients receiving triple therapy (HISTORIC): a randomised, placebo-controlled, double-blind, investigator-initiated trial","volume":"62","author":"Stolz","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ejim.2024.10.015_bib0072","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fphar.2011.00036","article-title":"Improvement of Airflow Limitation by Fluticasone Propionate\/Salmeterol in Chronic Obstructive Pulmonary Disease: What is the Specific Marker?","volume":"2","author":"Akamatsu","year":"2011","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ejim.2024.10.015_bib96","unstructured":"GOLD COPD Report 2019, available at: https:\/\/goldcopd.org, last accessed on September 13, 2024."},{"key":"10.1016\/j.ejim.2024.10.015_bib87","unstructured":"GOLD COPD Report 2024, available at: https:\/\/goldcopd.org, last accessed on September 13, 2024."},{"issue":"9","key":"10.1016\/j.ejim.2024.10.015_bib89","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S2213-2600(19)30190-0","article-title":"Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial","volume":"7","author":"Pascoe","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.ejim.2024.10.015_bib90","doi-asserted-by":"crossref","first-page":"1701162","DOI":"10.1183\/13993003.01162-2017","article-title":"Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD","volume":"50","author":"Casanova","year":"2017","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ejim.2024.10.015_bib91","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/thoraxjnl-2015-207021","article-title":"Blood eosinophils and inhaled corticosteroid\/long-acting \u03b2-2 agonist efficacy in COPD","volume":"71","author":"Pavord","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.ejim.2024.10.015_bib92","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12931-019-1268-7","article-title":"Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis","volume":"21","author":"Harries","year":"2020","journal-title":"Respir Res"},{"issue":"11","key":"10.1016\/j.ejim.2024.10.015_bib0073","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the Prevention of COPD Exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.10.015_bib0074","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2147\/COPD.S418944","article-title":"Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis","volume":"18","author":"Singh","year":"2023","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.ejim.2024.10.015_bib0075","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2147\/COPD.S294333","article-title":"Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO","volume":"16","author":"Pavord","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.ejim.2024.10.015_bib0076","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2147\/COPD.S438153","article-title":"Biological Anti-IL-5\/IL-5R Therapeutics for Chronic Obstructive Pulmonary Disease (COPD) with Specific Treatable Traits: A Real-World Retrospective Analysis","volume":"19","author":"Day de Larranaga","year":"2024","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"10.1016\/j.ejim.2024.10.015_bib93","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/02770903.2022.2036754","article-title":"Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience","volume":"60","author":"Matucci","year":"2023","journal-title":"J Asthma"},{"issue":"7","key":"10.1016\/j.ejim.2024.10.015_bib94","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jaip.2023.04.029","article-title":"Real-World Effectiveness Study of Benralizumab for Severe Eosinophilic Asthma: ZEPHYR 2","volume":"11","author":"Carstens","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.ejim.2024.10.015_bib0077","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Ralpha antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc'h","year":"2020","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.ejim.2024.10.015_bib0078","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ejim.2024.10.015_bib95","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.10.015_bib0079","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2147\/JAA.S413064","article-title":"Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR","volume":"16","author":"Laidlaw","year":"2023","journal-title":"J Asthma Allergy"},{"issue":"11","key":"10.1016\/j.ejim.2024.10.015_bib0080","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"18","key":"10.1016\/j.ejim.2024.10.015_bib0081","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","article-title":"Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma","volume":"385","author":"Wechsler","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejim.2024.10.015_bib0082","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","article-title":"Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial","volume":"9","author":"Rabe","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.ejim.2024.10.015_bib0083","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaci.2021.03.044","article-title":"Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial","volume":"148","author":"Kelsen","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.ejim.2024.10.015_bib0084","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S2213-2600(21)00556-7","article-title":"Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial","volume":"10","author":"Yousuf","year":"2022","journal-title":"Lancet Respir Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524004357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524004357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T02:32:36Z","timestamp":1736044356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620524004357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":95,"alternative-id":["S0953620524004357"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2024.10.015","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic obstructive pulmonary disease's eosinophilic phenotype: Clinical characteristics, biomarkers and biotherapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2024.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Federation of Internal Medicine. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}